{"id":"tienilic-acid","rwe":[{"pmid":"41218298","year":"2025","title":"Quantitative prediction of CYP2C9-mediated drug disposition using humanized mice.","finding":"","journal":"Drug metabolism and disposition: the biological fate of chemicals","studyType":"Clinical Study"},{"pmid":"39747333","year":"2025","title":"Prognostic signature and therapeutic drug identification for dilated cardiomyopathy based on necroptosis via bioinformatics and experimental validation.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"},{"pmid":"38641124","year":"2024","title":"HLM chip - A microfluidic approach to study the mechanistic basis of cytochrome P450 inhibition using immobilized human liver microsomes.","finding":"","journal":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","studyType":"Clinical Study"},{"pmid":"35953159","year":"2022","title":"Cytochrome P450s in chimeric mice with humanized liver.","finding":"","journal":"Advances in pharmacology (San Diego, Calif.)","studyType":"Clinical Study"},{"pmid":"35777846","year":"2022","title":"Defining the Selectivity of Chemical Inhibitors Used for Cytochrome P450 Reaction Phenotyping: Overcoming Selectivity Limitations with a Six-Parameter Inhibition Curve-Fitting Approach.","finding":"","journal":"Drug metabolism and disposition: the biological fate of chemicals","studyType":"Clinical Study"}],"tags":[{"label":"tienilic acid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"C03CC02","category":"atc"},{"label":"Active","category":"status"},{"label":"Hypertensive disorder","category":"indication"},{"label":"Approved 1970s","category":"decade"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Diuretics","category":"pharmacology"},{"label":"Gout Suppressants","category":"pharmacology"},{"label":"Natriuretic Agents","category":"pharmacology"},{"label":"Uricosuric Agents","category":"pharmacology"}],"phase":"marketed","safety":{"drugInteractions":[{"url":"/drug/cyp2c9-substrates","drug":"CYP2C9 Substrates","action":"Use caution","effect":"Strong CYP2C9 Inhibitors - CYP2C9 Substrates","source":"DrugCentral","drugSlug":"cyp2c9-substrates"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=tienilic acid","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:33:53.577391+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T02:34:10.500439+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:33:59.933594+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tienilic acid","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:34:01.078998+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL267744/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:34:02.182782+00:00"}},"allNames":"selacryn","offLabel":[],"synonyms":["ticrynafen","selacryn","thienylic acid","tienilic acid","tienylic acid"],"timeline":[{"date":"1979-05-02","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"aiSummary":"Selacryn, also known as ticrynafen, is a small molecule drug with an unknown mechanism of action. It was a loop diuretic and uricosuric agent used to treat hypertension, but was withdrawn from the market in 1982 due to reports of a link between its use and hepatitis.","approvals":[{"date":"1979-05-02","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Selacryn","ecosystem":[{"indication":"Hypertensive disorder","otherDrugs":[{"name":"acebutolol","slug":"acebutolol","company":"Promius Pharma"},{"name":"aliskiren","slug":"aliskiren","company":"Novartis"},{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","modality":"Small Molecule","drugClass":"tienilic acid","explanation":"","oneSentence":"","technicalDetail":"Selacryn acts as a non-competitive inhibitor of carbonic anhydrase, specifically targeting the enzyme's active site and preventing the conversion of carbon dioxide to bicarbonate and protons."},"commercial":{"launchDate":"1979","_launchSource":"DrugCentral (FDA 1979-05-02, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2658","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tienilic acid","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:54:55.967469","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:34:10.501063+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"ethacrynic acid","drugSlug":"ethacrynic-acid","fdaApproval":"1967-01-10","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"tienilic acid","indications":{"approved":[{"name":"Hypertensive disorder","source":"DrugCentral","snomedId":38341003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"ethacrynic-acid","brandName":"ethacrynic acid","genericName":"ethacrynic acid","approvalYear":"1967","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"002311","UNII":"HC95205SY4","CHEBI":"CHEBI:9590","INN_ID":"3036","UMLSCUI":"C0040209","chemblId":"CHEMBL267744","ChEMBL_ID":"CHEMBL267744","KEGG_DRUG":"D02386","DRUGBANK_ID":"DB04831","PUBCHEM_CID":"38409","SNOMEDCT_US":"64029000","MESH_DESCRIPTOR_UI":"D013989"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":223,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C03CC02","allCodes":["C03CC02"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Dec","pmid":"41218298","title":"Quantitative prediction of CYP2C9-mediated drug disposition using humanized mice.","journal":"Drug metabolism and disposition: the biological fate of chemicals"},{"date":"2025 Jan 2","pmid":"39747333","title":"Prognostic signature and therapeutic drug identification for dilated cardiomyopathy based on necroptosis via bioinformatics and experimental validation.","journal":"Scientific reports"},{"date":"2024 Jun 1","pmid":"38641124","title":"HLM chip - A microfluidic approach to study the mechanistic basis of cytochrome P450 inhibition using immobilized human liver microsomes.","journal":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences"},{"date":"2022","pmid":"35953159","title":"Cytochrome P450s in chimeric mice with humanized liver.","journal":"Advances in pharmacology (San Diego, Calif.)"},{"date":"2022 Jul 1","pmid":"35777846","title":"Defining the Selectivity of Chemical Inhibitors Used for Cytochrome P450 Reaction Phenotyping: Overcoming Selectivity Limitations with a Six-Parameter Inhibition Curve-Fitting Approach.","journal":"Drug metabolism and disposition: the biological fate of chemicals"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"1979","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1979-05-02T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:34:10.501063+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}